# Nordson Corporation Reports Second Quarter Fiscal 2025 Results and Third Quarter Guidance

#### Second Quarter Highlights:

- Sales were \$683 million, an increase of 5% year-over-year
- Earnings per diluted share were \$1.97
- Adjusted earnings per diluted share were \$2.42
- Backlog grew approximately 5% during the quarter

WESTLAKE, Ohio--(BUSINESS WIRE)--May 28, 2025--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal second quarter ended April 30, 2025. Sales were \$683 million compared to the prior year's second quarter sales of \$651 million. The second quarter 2025 sales included a favorable acquisition impact of 8%, offset by an organic sales decrease of 2% and unfavorable currency translation of less than 1%.

Net income was \$112 million, or \$1.97 of earnings per diluted share, compared to prior year's second quarter net income of \$118 million, or \$2.05 of earnings per diluted share. Excluding restructuring costs and acquisition related amortization, second quarter adjusted net income was \$138 million versus prior year adjusted net income of \$135 million. Second quarter adjusted earnings per diluted share were \$2.42, a 3% increase from the prior year adjusted earnings per diluted share of \$2.34.

EBITDA in the second quarter was \$217 million, or 32% of sales, an increase of 7% compared to prior year EBITDA of \$203 million, or 31% of sales.

Commenting on the Company's fiscal 2025 second quarter results, Nordson President and Chief Executive Officer Sundaram Nagarajan said, "We started the second quarter with increasing momentum in order entry, and our results outperformed the midpoint of our sales and earnings guidance. This was driven by strength in our electronics systems sales and steady growth in nonwovens systems, precision agriculture and medical fluid components. Also, our Atrion acquisition continues to perform above expectations. As expected, this growth was partially offset by year-over-year weakness in industrial systems sales, which improved sequentially compared to the first quarter. Operational excellence drove strong profit performance of 32% EBITDA despite the uncertain geopolitical environment. We also maintained our sound balance sheet and bought back \$85 million in shares during this dynamic quarter."

#### Second Quarter Segment Results

Industrial Precision Solutions sales of \$319 million decreased 8% from the prior year, inclusive of an organic sales decrease of 7% and unfavorable currency translation of 1%. The organic sales decrease was driven by weaker systems demand in polymer processing and industrial coatings product lines, partially offset by growth in nonwovens, precision agriculture and packaging product lines. Operating profit was \$96 million, a decrease of \$20 million from the prior year, reflecting the impact of lower volume. EBITDA in the quarter was \$114 million, or 36% of sales, compared to prior year second quarter EBITDA of \$128 million, or 37% of sales.

Medical and Fluid Solutions sales of \$203 million increased 20% compared to the prior year second quarter, inclusive of an acquisition impact of 30%, partially offset by an organic sales decrease of 10%. The organic sales decline reflects targeted program rationalization in medical contract manufacturing and ongoing destocking in selected interventional product lines. Operating profit was \$57 million, an increase of \$8 million from the prior year, reflecting contribution from the Atrion acquisition and solid operational execution from the organic business. EBITDA in the quarter was \$77 million, or 38% of sales, up 22% versus the prior year second quarter EBITDA of \$63 million, or 37% of sales.

Advanced Technology Solutions sales of \$161 million increased 18% organically compared to the prior year second quarter. The organic sales increase compared to prior year was driven by broad-based demand in semi-conductor and electronics end markets.

Operating profit was \$32 million, an increase of \$11 million due to the organic sales increase and the benefits of strategic cost and manufacturing optimization actions. EBITDA in the quarter was \$40 million, or 25% of sales, up 43% from the prior year second quarter EBITDA of \$28 million, or 20% of sales.

#### <u>Outlook</u>

Order entry remained strong during the quarter resulting in healthy backlog, up approximately 5% from the prior quarter. Based on current visibility and order entry trends, the Company expects third quarter fiscal 2025 sales to be in the range of \$710 to \$750 million. Third quarter adjusted earnings are forecasted to be in the range of \$2.55 to \$2.75 per diluted share.

Reflecting on the outlook and current macroeconomic environment, Nagarajan said, "Order entry and backlog support a third quarter performance that is in line with the full-year guidance we set at the beginning of our fiscal year. Our product portfolio is focused on differentiated products. Our decentralized and close-to-the-customer business model empowers our businesses to be responsive to customer needs. This includes the benefits of an in-region, for-region manufacturing strategy that will lead to growth with existing customers. Nordson has continuously demonstrated the ability to deliver best-in-class profitability in varying market scenarios, while remaining invested in the long-term growth priorities of the Company."

Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on Thursday, May 29, 2025, at 8:30 a.m. eastern time, which can be accessed at https://investors.nordson.com. Information about Nordson's investor relations and shareholder services is available from Lara Mahoney, vice president, investor relations and corporate communications at (440) 204-9985 or lara.mahoney@nordson.com.

The Company's definition of adjusted earnings excludes restructuring costs and acquisition related amortization for both current and historical periods. It is not possible for the Company to identify the amount or significance of future adjustments associated with acquisition and integration costs, restructuring costs, acquisition-related amortization, certain non-operating or income tax items, or other non-routine costs that the Company adjusts in the presentation of adjusted earnings guidance. These items are dependent on future events that are not reasonably estimable at this time. Accordingly, the Company is unable to reconcile without unreasonable effort the forecasted range of adjusted earnings guidance to a comparable GAAP range.

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," "target," or the negative of these terms or comparable terminology. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company's ability to successfully integrate acquisitions; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine, acts of terror, natural disasters and pandemics, including the recent coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company's most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, linkedin/Nordson, or www.facebook.com/nordson.

## CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(Dollars in thousands except for per-share amounts)

		Three Mor	nths	Ended	 Six Months Ended						
	April 30, 2025			pril 30, 2024	 April 30, 2025	P	April 30, 2024				
Sales	\$	682,938	\$	650,642	\$ 1,298,358	\$	1,283,835				
Cost of sales		309,034		284,765	588,558		569,531				
Gross profit		373,904		365,877	709,800		714,304				
Gross margin %		54.7 %		56.2 %	54.7 %		55.6 %				
Selling & administrative expenses		205,154		197,261	400,103		386,253				
Operating profit		168,750		168,616	309,697		328,051				
Interest expense - net		(26,019)		(18,555)	(51,637)		(38,953)				
Other expense - net		(3,961)		(785)	 (2,435)		(1,123)				
Income before income taxes		138,770		149,276	255,625		287,975				
Income taxes		26,366		31,059	 48,569		60,186				
Net income	\$	112,404	\$	118,217	\$ 207,056	\$	227,789				
Weighted-average common shares outstanding:											
Basic		56,785		57,222	56,960		57,142				
Diluted		57,038		57,681	57,265		57,617				
Earnings per share:											
Basic earnings	\$	1.98	\$	2.07	\$ 3.64	\$	3.99				
Diluted earnings	\$	1.97	\$	2.05	\$ 3.62	\$	3.95				

## CONSOLIDATED BALANCE SHEETS (Unaudited) (Dollars in thousands)

	Ap	ril 30, 2025	Oc	tober 31, 2024
Cash and cash equivalents	\$	130,157	\$	115,952
Receivables - net		624,057		594,663
Inventories - net		473,740		476,935
Other current assets		95,568	_	87,482
Total current assets		1,323,522		1,275,032
Property, plant and equipment - net		546,352		544,607
Goodwill		3,310,661		3,280,819
Other assets		881,503		900,508
	\$	6,062,038	\$	6,000,966
Notes payable and debt due within one year	\$	94,794	\$	103,928
Accounts payable and accrued liabilities		421,846		424,549
Total current liabilities		516,640		528,477
Long-term debt		2,118,739		2,101,197
Other liabilities		466,355		439,100
Total shareholders' equity		2,960,304	_	2,932,192
	\$	6,062,038	\$	6,000,966

## CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (Dollars in thousands)

	Six Mon	ths Ended
	April 30, 2025	April 30, 2024
Cash flows from operating activities:		
Net income	\$ 207,056	\$ 227,789
Depreciation and amortization	74,608	66,264
Other non-cash items	7,021	10,281
Changes in operating assets and liabilities and other	(10,393)	(9,370)
Net cash provided by operating activities	278,292	294,964
Cash flows from investing activities:		
Additions to property, plant and equipment	(37,439)	) (21,907)
Other - net	10,339	6,730
Net cash used in investing activities	(27,100)	) (15,177)
Cash flows from financing activities:		
Net repayment of long-term debt	(5,800)	) (204,372)
Repayment of finance lease obligations	(2,627)	) (2,881)
Dividends paid	(88,937)	) (77,796)
Issuance of common shares	2,803	27,219
Purchase of treasury shares	(146,252)	(7,927)
Net cash used in financing activities	(240,813)	(265,757)
Effect of exchange rate change on cash:	3,826	(4,263)
Net change in cash and cash equivalents	14,205	9,767
Cash and cash equivalents:		
Beginning of period	115,952	115,679
End of period	\$ 130,157	\$ 125,446

## SALES BY GEOGRAPHIC SEGMENT (Unaudited) (Dollars in thousands)

		Three Mor	nths	Ended	Sales Variance							
	Ap	ril 30, 2025	Ар	ril 30, 2024	Organic	Acquisitions	Currency	Total				
SALES BY SEGMENT												
Industrial Precision Solutions	\$	318,847	\$	344,978	(6.9)%	%	(0.7)%	(7.6)%				
Medical and Fluid Solutions		202,809		168,966	(10.0)%	30.0 %	<u> </u>	20.0 %				
Advanced Technology Solutions		161,282		136,698	18.1 %	<u> </u>	(0.1)%	18.0 %				
Total sales	\$	682,938	\$	650,642	(2.4)%	7.8 %	(0.4)%	5.0 %				
<u>SALES BY GEOGRAPHIC</u> REGION												
Americas	\$	292,463	\$	294,428	(12.2)%	12.4 %	(0.9)%	(0.7)%				
Europe		172,496		182,070	(10.7)%	4.7 %	0.7 %	(5.3)%				
Asia Pacific		217,979		174,144	22.6 %	3.2 %	(0.6)%	25.2 %				
Total sales	\$	682,938	\$	650,642	(2.4)%	7.8 %	(0.4)%	5.0 %				
		Six Mont	ths E	Ended	Sales Variance							
	Ap	ril 30, 2025	Ар	ril 30, 2024	Organic	Acquisitions	Currency	Total				
SALES BY SEGMENT												

<u>SALES BY SEGMENT</u>						
Industrial Precision Solutions	\$ 619,295	\$ 682,720	(7.6)%	— %	(1.7)%	(9.3)%
Medical and Fluid Solutions	396,418	328,492	(10.6)%	31.7 %	(0.4)%	20.7 %
Advanced Technology Solutions	 282,645	 272,623	4.3 %	<u> </u>	(0.6)%	3.7 %
Total sales	\$ 1,298,358	\$ 1,283,835	(5.8)%	8.1 %	(1.2)%	1.1 %

#### SALES BY GEOGRAPHIC REGION

REGION						
Americas	\$ 560,300	\$ 568,440	(13.4)%	13.0 %	(1.0)%	(1.4)%
Europe	340,259	361,380	(10.0)%	5.2 %	(1.0)%	(5.8)%
Asia Pacific	 397,799	 354,015	10.7 %	3.2 %	(1.5)%	12.4 %
Total sales	\$ 1,298,358	\$ 1,283,835	(5.8)%	8.1 %	(1.2)%	1.1 %

## RECONCILIATION OF NON-GAAP MEASURES - NET INCOME TO EBITDA (Unaudited) (Dollars in thousands)

		Three Mor	Ended	Six Months Ended				
	Apr	il 30, 2025	Ар	ril 30, 2024	Apr	il 30, 2025	Apr	il 30, 2024
Net income	\$	112,404	\$	118,217	\$	207,056	\$	227,789
Income taxes		26,366		31,059		48,569		60,186
Interest expense - net		26,019		18,555		51,637		38,953
Other (income) expense - net		3,961		785		2,435		1,123
Depreciation and amortization		37,578		32,720		74,608		66,264
Inventory step-up amortization <sup>(1)</sup>		_		_		3,135		2,944
Severance and other <sup>(1)</sup>		10,313		2,078		16,274		2,078
Acquisition-related costs <sup>(1)</sup>		513				1,543		597
EBITDA (non-GAAP) <sup>(2)</sup>	\$	217,154	\$	203,414	\$	405,257	\$	399,934

<sup>(1)</sup> Represents cost reduction actions as well as fees and non-cash inventory charges associated with acquisitions.

<sup>(2)</sup> EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as cost reduction actions, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.

### RECONCILIATION OF NON-GAAP MEASURES - EBITDA (Unaudited)

(Dollars in thousands)

	Thr	ee Months Ended	Si	ix Months Ended
	April 30, 20	025 April 30, 2	2024 April 30, 2	2025 April 30, 2024
SALES BY SEGMENT				
Industrial Precision Solutions	\$ 318,847	\$ 344,978	\$ 619,295	\$ 682,720
Medical and Fluid Solutions	202,809	168,966	396,418	328,492
Advanced Technology Solutions	161,282	136,698	282,645	272,623
Total sales	\$ 682,938	\$ 650,642	\$1,298,358	\$1,283,835
OPERATING PROFIT				
Industrial Precision Solutions	\$ 95,722	\$ 115,922	\$ 191,434	\$ 225,020
Medical and Fluid Solutions	56,805	48,993	97,741	95,093
Advanced Technology Solutions	31,558	20,693	49,681	38,997
Corporate	(15,335)	(16,992)	(29,159)	(31,059)
Total operating profit	\$ 168,750	\$ 168,616	\$ 309,697	\$ 328,051
<b>OPERATING PROFIT ADJUSTME</b>	<u>NTS (1)</u>			
Industrial Precision Solutions	\$ 5,212	\$ —	\$ 9,823	\$ 3,541
Medical and Fluid Solutions	1,366	—	6,621	—
Advanced Technology Solutions	3,288	2,078	3,288	2,078
Corporate	960		1,220	
Total adjustments	\$ 10,826	\$ 2,078	\$ 20,952	\$ 5,619
<b>DEPRECIATION &amp; AMORTIZATIO</b>	<u>ON</u>			
Industrial Precision Solutions	\$ 12,614	\$ 12,437	\$ 25,067	\$ 25,357
Medical and Fluid Solutions	18,367	13,564	36,508	27,269
Advanced Technology Solutions	4,670	4,767	9,318	9,668
Corporate	1,927	1,952	3,715	3,970
Total depreciation & amortization	\$ 37,578	\$ 32,720	\$ 74,608	\$ 66,264
EBITDA (NON-GAAP) <sup>(2)</sup>				
	¢ 112 540	2(0/ \$ 129.250	270/ \$ 226.224	270/ \$ 252.019 270/
Industrial Precision Solutions	\$ 113,548 76,528	36% \$ 128,359	37% \$ 226,324	37% \$ 253,918 37%
Medical and Fluid Solutions	76,538	38% 62,557	37% 140,870	36% 122,362 37% 22% 50,742 10%
Advanced Technology Solutions	39,516	25% 27,538	20% 62,287	22% 50,743 19%
Corporate	(12,448)	(15,040)	(24,224)	(27,089)
Total EBITDA	\$ 217,154	32% <u>\$ 203,414</u>	31% <u>\$ 405,257</u>	31% <u>\$ 399,934</u> 31%

<sup>(1)</sup> Represents cost reduction actions as well as fees and non-cash inventory charges associated with acquisitions.

<sup>(2)</sup> EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as cost reduction actions, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.

### RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED NET INCOME AND EARNINGS PER SHARE (Unaudited) (Dollars in thousands)

		Three Mo	Ended	Six Months Ended				
	Ap	April 30, 2025 April 30, 2024		Aŗ	oril 30, 2025	April 30, 2024		
GAAP AS REPORTED								
Operating profit	\$	168,750	\$	168,616	\$	309,697	\$	328,051
Other / interest expense - net		(29,980)		(19,340)		(54,072)		(40,076)
Net income		112,404		118,217		207,056		227,789
Diluted earnings per share	\$	1.97	\$	2.05	\$	3.62	\$	3.95
Shares outstanding - diluted		57,038		57,681		57,265		57,617
<b>OPERATING PROFIT ADJUSTMENTS</b>								
Inventory step-up amortization	\$	—	\$	—	\$	3,135	\$	2,944
Acquisition costs		513		_		1,543		597
Severance and other		10,313		2,078		16,274		2,078
ACQUISITION AMORTIZATION OF	¢	10 60 6	<b>.</b>	10.000		• • • • •		
INTANGIBLES	\$	19,696	\$	18,823		39,007		38,210
NON-OPERATING EXPENSE ADJUSTMENTS								
Entity liquidation	\$	988	\$	_	\$	988	\$	
Total adjustments	\$	31,510	\$	20,901	\$	60,947	\$	43,829
Adjustments net of tax	\$	25,523	\$	16,556	\$	49,367	\$	34,669
Other discrete tax items	\$	—	\$	_	\$	_	\$	_
EPS effect of adjustments and other discrete tax items	\$	0.45	\$	0.29	\$	0.86	\$	0.60
NON-GAAP MEASURES-ADJUSTED								
<b>OPERATING PROFIT, NET INCOME AND</b>								
ADJUSTED EARNINGS PER SHARE	¢	150 556	<i>•</i>	150 (04	¢	220 (10	¢	222 (50
Operating profit <sup>(1)</sup>	\$	179,576	\$	170,694	\$	330,649	\$	333,670
Operating profit % of sales	¢	26.3 %		26.2 %		25.5 %		26.0 %
Net income <sup>(1)</sup>	\$	137,927	\$	134,773	\$	256,423	\$	262,458
Diluted earnings per share <sup>(2)</sup>	\$	2.42	\$	2.34	\$	4.48	\$	4.55

<sup>(1)</sup> Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items. Refer to the "Reconciliation of Non-GAAP measures - EBITDA" table for definition of adjustments to operating income.

<sup>(2)</sup> Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items.

#### RECONCILIATION OF NON-GAAP MEASURES - OPERATING CASH FLOW TO FREE CASH FLOW (Unaudited) (Dollars in thousands)

	Year to Date				
	Ap	oril 30, 2025	Jar	nuary 31, 2025	
Net cash provided by operating activities		278,292	\$	159,122	
Additions to property, plant and equipment		(37,439)		(21,399)	
Free Cash Flow - Year to Date <sup>(1)</sup>		240,853		137,723	
Net Income - Year to Date	\$	207,056	\$	94,652	
Free Cash Flow Conversion <sup>(2)</sup>		116 %	146 %		
		Year	to Da	ate	
	April 30, 2024 January 31, 20				
Net cash provided by operating activities	\$	294,964	\$	172,356	
Additions to property, plant and equipment		(21,907)		(7,530)	
Free Cash Flow - Year to Date <sup>(1)</sup>		273,057		164,826	

<sup>(1)</sup> Free Cash Flow - Year to Date is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Net cash provided by operating activities minus Additions to property, plant and equipment.

<sup>(2)</sup> Free Cash Flow Conversion - Year to Date is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Free Cash Flow - Year to Date divided by Net Income - Year to Date.

Management uses certain non-GAAP measures, such as adjusted net income, adjusted EPS and EBITDA, internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding.

Contact Lara Mahoney Vice President, Investor Relations & Corporate Communications 440.204.9985 Lara.Mahoney@nordson.com